WallStreetZenWallStreetZen

NASDAQ: PRFX
Painreform Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their PRFX stock forecasts and price targets.

Forecast return on equity

Is PRFX forecast to generate an efficient return?

Company
-858.04%
Industry
161.03%
Market
344.29%
PRFX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PRFX forecast to generate an efficient return on assets?

Company
-649.02%
Industry
90.8%
PRFX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PRFX earnings per share forecast

What is PRFX's earnings per share in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$35.99-186.19%

PRFX revenue forecast

What is PRFX's revenue in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0

PRFX vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
PRFX$0.69N/AN/A
UPC$4.42N/AN/A
AKAN$1.28N/AN/A
RDHL$1.22N/AN/A
SHPH$2.02N/AN/A
View Top Pharmaceutical Stocks

Painreform Stock Forecast FAQ

What is PRFX's earnings growth forecast for 2026-2026?

(NASDAQ: PRFX) Painreform's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.

Painreform's earnings in 2026 is -$4,086,000.

In 2026, PRFX is forecast to generate -$72,444,087 in earnings, with the lowest earnings forecast at -$69,603,142 and the highest earnings forecast at -$74,574,795.

If you're new to stock investing, here's how to buy Painreform stock.

What is PRFX's revenue growth forecast for 2026-2026?

(NASDAQ: PRFX) Painreform's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.

Painreform's revenue in 2026 is $0.

In 2026, PRFX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is PRFX's forecast return on assets (ROA) for 2026-2026?

(NASDAQ: PRFX) forecast ROA is -649.02%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 90.8%.

What is PRFX's Earnings Per Share (EPS) forecast for 2026-2026?

(NASDAQ: PRFX) Painreform's current Earnings Per Share (EPS) is $41.75. In 2026, PRFX's EPS is forecast to hit -$35.99 (min: -$34.57, max: -$37.04).

What is PRFX's forecast return on equity (ROE) for 2026-2026?

(NASDAQ: PRFX) forecast ROE is -858.04%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.